Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharma-backed TransCelerate makes progress on clinical trial efficiency

This article was originally published in SRA

Executive Summary

TransCelerate BioPharma, the non-profit organization founded by 10 big pharma companies to quickly address issues that hamper clinical trial efficiency, has taken swift action on all five of the objectives the group outlined in 2012 when it was first established. In addition, the group has adopted a list of five new priorities.

You may also be interested in...



Reliance On ‘Digitized Paper’ Is Slowing Drug Development – US FDA’s Woodcock

Efficient development and review is being hindered by the inability to exchange data freely and truly capitalize on the digital age, CDER director says, challenging industry, regulators and others to creatively think about how to move away from legacy, paper-based processes in clinical trials and regulatory submissions.

Finance Watch: Seed/Series A Financings Benefit As Big Crossover Rounds Slow

Silicon Valley Bank data show a pullback in crossover financings but an increase in seed and series A venture capital rounds. In recent private company financings, CRO Novotech raised $760m. In public company financings, Eleusis will merge with a SPAC and the Bausch + Lomb IPO is on file with the SEC.

ImmPACT Raises $110m As Bispecific CAR-T Shows Promising Response Rates

ImmPACT Bio is advancing three CAR-T technology platforms that aim to address problems such as antigen escape, off-target toxicities and the immunosuppressive tumor microenvironment. 

UsernamePublicRestriction

Register

PS117854

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel